Two-year Efficacy of tocilizumab in Patients With Active Rheumatoid Arthritis in Clinical Practice

Ferreira, Irene; González, Miguel Angel Ferrer; Garrido, Pilar Morales; Utrilla, A; Sánchez, Antonio García; Pino, María Teresa; Rosario, Evelyn Suero; Hernandez, Cristina; Oñate, I. Añón; Albaladejo, L. Pérez; Cáliz, Rafael

doi:10.1016/j.reumae.2016.03.008

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The retention rates reported with other biologics are generally similar to those reported in the current analysis for abatacept (online supplemental table S3 ) [ 31 – 35 ]. In the clinical practice setting, a 61% retention rate was observed at 2 years for tocilizumab [ 35 ], whereas a registry study reported 3-year tocilizumab retention rates as 52% in bDMARD-naïve patients and 51% and 47% in patients with 1 or 2 prior bDMARD failures, respectively [ 32 ]. A population-based prospective study in France reported 2-year retention rates of 69% for rituximab, 39% for abatacept, and 63% for tocilizumab in patients with RA in routine practice [ 23 ].…”

Section: Discussionsupporting

confidence: 78%

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

et al. 2022

View full text Add to dashboard Cite

Objectives To evaluate retention, efficacy, and safety of subcutaneous (SC) abatacept over 2 years in patients with moderate-to-severe RA in the Abatacept SubCutaneOus in Routine clinical practicE (ASCORE) study. Methods Patients with RA who initiated SC abatacept 125 mg once weekly were enrolled in the international, observational, prospective multicentre ASCORE study into biologic-naïve or ≥ 1 prior biologic failure cohorts. Primary endpoint: abatacept retention rate at 2 years. Secondary endpoints: proportion of patients with good/moderate EULAR response rates based on DAS28 (ESR), low disease activity and/or remission according to DAS28 (ESR; ≤ 3.2/ < 2.6), SDAI (≤ 11/ ≤ 3.3), CDAI (≤ 10/ ≤ 2.8), and Boolean criteria. Retention rate by baseline serostatus was evaluated post hoc. Results Overall, 47% of patients remained on abatacept for 2 years, irrespective of treatment line. Higher abatacept retention rates were associated with lower prior biologic exposure. Generally, clinical outcomes showed that the proportion of patients with low disease activity/remission was higher in biologic-naïve patients (vs biologic-failure) and similar in those with 1 and ≥ 2 prior biologic failures. In patients on treatment at 2 years, good/moderate EULAR response rates of ~ 80% were consistently noted irrespective of prior biologic exposure. Across treatment lines, retention was greater in patients with seropositive (vs seronegative) RA. Patients with rheumatoid factor/anti-citrullinated protein antibody single-positive RA who were bio-naïve had higher retention than patients who were bio-experienced. Conclusions In the ASCORE study, SC abatacept retention was 47% at 2 years with good clinical outcomes and was well-tolerated in the real-world setting. Abatacept retention and clinical response rates were higher in patients who received abatacept as an earlier- versus later-line biologic drug treatment and in those with seropositive RA. Trial registration ClinicalTrials.gov, NCT02090556.

show abstract

Section: Discussionsupporting

confidence: 78%

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a smaller, single center observational study, the subgroup of patients who were RF-positive actually had a better response to tocilizumab 13 . In an open label study of 85 patients treated with tocilizumab from Spain, there was no difference in response by CCP or RF status 14 . In one phase IIIB clinical trial, there was no difference by RF status 15 .…”

Section: Discussionmentioning

confidence: 93%

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Cappelli

Palmer²,

Kremer

et al. 2017

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Objective Autoantibodies can be useful in predicting response to certain treatments in rheumatoid arthritis (RA). We aimed to evaluate initial response to tocilizumab (TCZ) by change in physician and patient reported outcomes and laboratory parameters in a real world cohort of patients with RA. We analyzed data by autoantibody status to determine whether patients with seronegative RA had improved response to tocilizumab when compared to their seropositive counterparts. Methods Data from the CORRONA RA registry was analyzed. Patients were included if they were started on TCZ and had data from a follow up visit 4-8 months after initiation, as well as having information on serologic status. Serologic status was determined by presence of anti-cyclic citrullinated peptide (CCP) antibodies. Changes in disease activity measures from baseline to follow up visit were evaluated. Results Both CCP negative and positive groups had statistically significant improvement in physician reported measurements (physician rating of disease activity, joint counts), patient reported measures (disease activity, pain, fatigue), and acute phase reactants after 4-8 months of treatment with tocilizumab. The magnitude of improvement, however, did not differ significantly by CCP status. Conclusion Tocilizumab led to statistically significant improvement in all patient and physician reported measures of disease activity evaluated in this cohort of patient with RA. The response to tocilizumab did not differ by CCP status.

show abstract

Discontinuation of biologic and target-specific therapy in patients with rheumatoid arthritis: a retrospective cohort study

Neycheva,

Naseva,

Batalov

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

Two-year Efficacy of tocilizumab in Patients With Active Rheumatoid Arthritis in Clinical Practice

Cited by 4 publications

References 32 publications

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Discontinuation of biologic and target-specific therapy in patients with rheumatoid arthritis: a retrospective cohort study

Contact Info

Product

Resources

About